In this module, we present different immunotherapy techniques, their therapeutic potential and the history of this type of treatment.
Basics of immuno-oncology
Univadis Oncology eLearning
1. Borghaei H et al; Immunotherapy of cancer. Eur J Pharmacol. 2009; 625:41-54
2. Kapoor A et al: Malignancy in kidney transplant recipients. Drugs 68, 2008, S. 11–19
3. C. V. Ichim: Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. In: J Transl Med 3, 2005; 8;3(1):8.
4. P. Ehrlich: Über den jetzigen Stand der Karzinomforschung. In: Ned Tijdschr Geneeskd 5, 1909, S. 273–290..
5. Hanahan Weinber D et al; Hallmarks of cancer: the next generation; Cell (2011); 144 (5): 646-74;
6. Baxevanis CN et al; Therapeutic cancer vaccines: a long and winding road to success; Expert Rev Vaccines. 2014 Jan;13(1):131-44
7. Dolan DE et al; PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy; Cancer Control (2014); 21(3): 231-7
Responsible for the content: © 2015 KWHC GmbH, Alewinstr. 13, 29525 Uelzen (Germany). The image sources can be found at: http://www.kwhc.de/webpage/index.php/oncology-nurses-copyrights.html
50mins - Expert presentations By Centers for Disease Control and Prevention
Zika Virus—What Clinicians Need to Know
Experts from the CDC present a comprehensive overview: Zika Virus-What Clinicians Need to Know, and provide responses to selected questions
9mins - Expert presentations By Vicky Tittle
Dr Vicky Tittle, from 56 Dean Street in London, UK, reviews the reasons to test for HIV, when and how to test and which key populations should receive testing. Specific focus is placed on British guidelines for HIV testing and importance to conduct key initial investigations.
13mins - Expert presentations By Professor David Livermore
Future developments in antimicrobial agents
Professor David Livermore highlights increasing resistance and the major bacterial challenges we face. Beta-lactams, the most widely used antibiotic are losing their efficacy. However, there is hope for antimicorbial agents. Cefiderocol, murepavadin and gepotidacin/zoliflodacin all show promise in replacing spent antibiotics. Further, non-antibiotic approaches and improved molecular diagnostics, while not currently comprehensive, could revolutionise the field.